In several studies, ARID2 mutations and/or lower protein expression of ARID2 have been reported to correspond to poor patient prognosis in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, breast cancer, oral SCC, and lung cancer47–51. This evidence concerns the gene ARID2 and intrahepatic cholangiocarcinoma.